Janus Henderson Group PLC trimmed its position in Iqvia Holdings Inc (NYSE:IQV) by 7.3% during the third quarter, Holdings Channel reports. The fund owned 2,741,814 shares of the medical research company’s stock after selling 216,476 shares during the quarter. Janus Henderson Group PLC’s holdings in Iqvia were worth $355,723,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. boosted its position in Iqvia by 5.7% in the second quarter. BlackRock Inc. now owns 10,170,048 shares of the medical research company’s stock valued at $1,015,173,000 after buying an additional 546,878 shares in the last quarter. Alliancebernstein L.P. boosted its position in Iqvia by 4.9% in the third quarter. Alliancebernstein L.P. now owns 2,534,788 shares of the medical research company’s stock valued at $328,864,000 after buying an additional 118,411 shares in the last quarter. Northern Trust Corp boosted its position in Iqvia by 7.0% in the second quarter. Northern Trust Corp now owns 1,877,470 shares of the medical research company’s stock valued at $187,408,000 after buying an additional 122,260 shares in the last quarter. First Trust Advisors LP boosted its position in Iqvia by 37.7% in the third quarter. First Trust Advisors LP now owns 1,367,920 shares of the medical research company’s stock valued at $177,474,000 after buying an additional 374,866 shares in the last quarter. Finally, Morgan Stanley boosted its position in Iqvia by 0.3% in the second quarter. Morgan Stanley now owns 1,214,945 shares of the medical research company’s stock valued at $121,278,000 after buying an additional 4,093 shares in the last quarter. 93.71% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have weighed in on the stock. Robert W. Baird raised their target price on shares of Iqvia from $143.00 to $146.00 and gave the company an “outperform” rating in a research report on Tuesday, October 2nd. UBS Group assumed coverage on shares of Iqvia in a research report on Tuesday, October 9th. They issued a “buy” rating on the stock. Raymond James raised their target price on shares of Iqvia from $136.00 to $145.00 and gave the company a “strong-buy” rating in a research report on Friday, August 31st. Argus set a $136.00 target price on shares of Iqvia and gave the company a “buy” rating in a research report on Thursday, August 23rd. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $97.00 target price on shares of Iqvia in a research report on Wednesday, July 25th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $133.53.

Shares of NYSE:IQV opened at $115.85 on Wednesday. The firm has a market cap of $23.35 billion, a PE ratio of 26.57, a price-to-earnings-growth ratio of 1.66 and a beta of 0.81. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.41. Iqvia Holdings Inc has a 52 week low of $91.57 and a 52 week high of $135.48.

Iqvia (NYSE:IQV) last issued its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.03. The company had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. Equities analysts anticipate that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.

In other news, Director John G. Danhakl sold 370,470 shares of Iqvia stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total transaction of $46,245,770.10. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 9,216 shares of Iqvia stock in a transaction on Friday, September 7th. The stock was sold at an average price of $126.46, for a total transaction of $1,165,455.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 601,586 shares of company stock worth $75,510,422. 6.00% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/11/21/iqvia-holdings-inc-iqv-position-cut-by-janus-henderson-group-plc.html.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Article: How to read a candlestick chart

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.